News coverage about Medtronic (NYSE:MDT) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medtronic earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media stories about the medical technology company an impact score of 46.6774488787037 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Medtronic (NYSE MDT) opened at $78.38 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.05 and a current ratio of 2.40. The firm has a market capitalization of $110,110.00, a PE ratio of 21.53, a price-to-earnings-growth ratio of 2.25 and a beta of 0.93. Medtronic has a twelve month low of $75.44 and a twelve month high of $89.72.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.08. The firm had revenue of $7.05 billion for the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 earnings per share. equities analysts predict that Medtronic will post 4.76 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, January 19th. Shareholders of record on Friday, December 29th were issued a dividend of $0.46 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $1.84 annualized dividend and a yield of 2.35%. Medtronic’s dividend payout ratio is presently 50.55%.

Several research firms have recently issued reports on MDT. Oppenheimer set a $94.00 price target on Medtronic and gave the stock a “buy” rating in a research report on Friday, January 19th. Morgan Stanley raised their price target on Medtronic from $91.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Monday. Stifel Nicolaus raised their price target on Medtronic from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Wednesday, November 22nd. Jefferies Group restated a “buy” rating and issued a $99.00 price target on shares of Medtronic in a research report on Thursday, November 23rd. Finally, Zacks Investment Research upgraded Medtronic from a “sell” rating to a “hold” rating in a research report on Thursday, November 23rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $90.10.

In other news, EVP Bryan C. Hanson sold 16,000 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $82.82, for a total value of $1,325,120.00. Following the sale, the executive vice president now directly owns 88,818 shares in the company, valued at $7,355,906.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Richard Kuntz sold 78,526 shares of the business’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total value of $6,769,726.46. Following the completion of the sale, the vice president now owns 149,761 shares in the company, valued at $12,910,895.81. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 136,684 shares of company stock worth $11,582,596. Corporate insiders own 0.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at

Medtronic Company Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Insider Buying and Selling by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with's FREE daily email newsletter.